Revvity, Inc. (RVTY)
Health Care · Health Care Equipment · US stock · S&P 500 component
$157.36
▲ +0.75 (0.48%)
Fair valueFair
$134 −14.8% to fair value
$67fair band $114–$163$201
Day's range
$154.89 – $161.52
52-week range
$81.22 – $166.25
About Revvity, Inc.
Revvity is a life sciences and diagnostics company that was formerly known as PerkinElmer. It supplies instruments, reagents, software and services used by researchers and drug developers, and it provides diagnostic tests including newborn and prenatal screening and immunodiagnostics. Customers are pharmaceutical and biotechnology firms, academic laboratories, hospitals, clinical laboratories and public health bodies. The business is organised into life sciences and diagnostics segments.
Revenue of $2.9 billion over the last twelve months comes from recurring reagents and tests, instruments and software. Revenue has changed at -4.8% a year across the last three years. The operating margin is 12.3%, the business earns 3% on the capital invested in it, and net debt is 2.8 times EBITDA. The dividend yield is 0.1%. On the site's X-Ray Score it receives 26 out of 100.
Price chart
52-wk range $81.22 – $166.25Volume 1,779,722Daily, split-adjusted
Vitals
Market cap$17.6B
52-week range$81.22 – $166.25
Volume (last day)1,779,722
P/E (TTM)75.4
EBIT / EV yield1.8%
Free-cash-flow yield3.2%
Dividend yield0.1%
Revenue (TTM)$2.9B
Net income (TTM)$238M
Operating margin12.3%
Return on capital3.4%
Debt incl. leases$3.2B
Cash & securities$1.0B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$134middle half of models $131 – $138
Fair
−14.8% to fair value
Average of the 10 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Low, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $157
Undervalued < $114Fair $114 – $163Overvalued > $163
P/E multiple
$145
P/B multiple
$138
P/S multiple
$131
EV/EBITDA multiple
$137
EV/EBIT multiple
$116
EV/revenue multiple
$136
10-year DCF, EBITDA exit
$131
5-year DCF, EBITDA exit
$138
10-year DCF, revenue exit
$130
5-year DCF, revenue exit
$139
10-year DCF, growth exit · not used
$49
5-year DCF, growth exit · not used
$38
Dividend discount, stable · not used
$9
Dividend discount, multi-stage · not used
$10
Earnings power value · not used
$56
Growth the price implies
32.1%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Weak
20/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield1.8%
Free-cash-flow yield3.2%
Fair value vs price0.9×
Growth
Weak
19/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-4.8%
EPS growth (3y)-22.8%
Growth consistency80%
Profitability
Weak
25/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital3.4%
Operating margin12.3%
Financial health
Weak
39/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA2.8×
Interest cover3.8×
Dividends
Weak
28/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.1%
Dividends vs free cash flow4%
Dividend growth-2.5%
Quarterly results: last 6 quarters
+2.3%
Mar '25
+4.1%
Jun '25
+2.2%
Sep '25
+5.9%
Dec '25
+7.0%
Apr '26
+1.3%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $730M, diluted EPS $0.47.
Compare with peers
DXCM Dexcom Inc78 PODD Insulet Corp72 RMD Resmed Inc70 BSX Boston Scientific Corp67Other Health Care Equipment companies by X-Ray Score.
SWOT analysis: Revvity, Inc.
Strengthsinside the company
- No standout strength in the figures we track.
Weaknessesinside the company
- Return on invested capital is only 3.4% (median 10.7% for industry peers), so the business earns little above its cost of capital.
- Revenue has fallen 4.8% a year over three years while industry peers grew 9.4%.
- Earnings per share have declined 22.8% a year over three years.
Opportunitiesvaluation and setting
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- Trades at 73.9x earnings, 150% above the 29.5x median of industry peers, so the price already assumes better results.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare RVTY with peers and sector
Medians of 15 Health Care Equipment peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): ABT 41, ISRG 62, MDT 57, SYK 56, BSX 67, BDX 47.
| Metric | RVTY | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 26 | 57 | 49 |
| Valuation | 20 | 60 | 55 |
| Growth | 19 | 74 | 48 |
| Profitability | 25 | 55 | 51 |
| Financial health | 39 | 64 | 48 |
| Dividends | 28 | 57 | 52 |
Sector leaders: highest X-Ray Score in Health Care
RVTY ranks #57 of 60 in Health Care and #16 of 16 in Health Care Equipment by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for RVTY
Each factor is rated by where RVTY stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 3 Good · 6 Average · 12 Bad of 21
Growth: 0 · 0 · 3
Profitability: 0 · 2 · 2
Financial strength: 1 · 1 · 2
Valuation: 1 · 1 · 3
Cash flow: 1 · 2 · 1
Efficiency: 0 · 0 · 1
| Factor | RVTY | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | −4.8% | Bad beats 4% | +5.5% | – | – |
| Revenue growth, last year | +3.7% | Bad beats 26% | +7.1% | +0.2% | ▲ Better |
| EPS growth, 3 years a year | −22.8% | Bad beats 10% | +5.0% | – | – |
| Profitability | |||||
| Operating margin | 12.3% | Average beats 36% | 16.4% | 12.6% | ≈ In line |
| Net margin | 8.2% | Average beats 34% | 11.1% | 17.2% | ▼ Worse |
| Return on invested capital | 3.4% | Bad beats 13% | 12.2% | – | – |
| Return on equity | 3.3% | Bad beats 12% | 13.7% | 7.7% | ▼ Worse |
| Financial strength | |||||
| Net debt / EBITDA | 2.8x | Average beats 38% | 2.0x | 3.0x | ≈ In line |
| Interest cover | 3.8x | Bad beats 19% | 9.4x | 3.7x | ≈ In line |
| Current ratio | 1.80 | Good beats 68% | 1.52 | 2.07 | ▼ Worse |
| Piotroski F-score | 5 / 9 | Bad beats 25% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 73.9x | Bad beats 7% | 28.2x | 31.1x | ▼ Worse |
| Price / book | 2.4x | Good beats 77% | 3.7x | 1.8x | ▼ Worse |
| Price / sales | 6.0x | Average beats 34% | 3.7x | 5.0x | ▼ Worse |
| EV / EBITDA | 25.6x | Bad beats 32% | 17.6x | 18.5x | ▼ Worse |
| Free cash flow yield | 3.2% | Bad beats 30% | 4.4% | 3.9% | ≈ In line |
| Cash flow | |||||
| Free cash flow margin | 19.2% | Average beats 61% | 16.3% | 17.9% | ≈ In line |
| Cash from operations / net income | 2.64 | Good beats 87% | 1.61 | 1.50 | ▲ Better |
| Free cash flow growth, 3 years a year | −5.0% | Bad beats 28% | +4.3% | – | – |
| Accruals (lower is better) | −3.2% | Average beats 40% | −3.9% | – | – |
| Efficiency | |||||
| Days sales outstanding | 89 days | Bad beats 12% | 62 days | 84 days | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 1 Good · ● 4 Average · ● 10 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAAverage
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 27/100.
Financials
| FY22 | FY23 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| Operating income | $1.3B | $743M | $301M | $347M | $357M |
| Net income | $943M | $569M | $693M | $270M | $241M |
| Operating cash flow | $1.4B | $680M | $91M | $628M | $583M |
| Operating margin | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% |
| Free cash flow | $1.3B | $594M | $10M | $542M | $509M |
| Diluted EPS | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 154.5 | Bullish |
| EMA 10 | 154.5 | Bullish |
| SMA 20 | 153.5 | Bullish |
| EMA 20 | 151.7 | Bullish |
| SMA 50 | 139.3 | Bullish |
| EMA 50 | 141.1 | Bullish |
| SMA 100 | 124.0 | Bullish |
| EMA 100 | 128.7 | Bullish |
| SMA 200 | 110.1 | Bullish |
| EMA 200 | 116.9 | Bullish |
Oscillators (daily)
| RSI (14) | 64.07 | Neutral |
| MACD (12, 26) | 4.53 | Bullish |
| Momentum (12) | 2.65 | Bullish |
| Stochastic %K (14) | 54.53 | Neutral |
| Williams %R (14) | -45.47 | Neutral |
| CCI (20) | 154.9 | Bearish |
Pivot points (classic, last session)
S3 147.7 | S2 151.3 | S1 154.3 | Pivot 157.9 | R1 161.0 | R2 164.6 | R3 167.6 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.28 USD
Yield on today's price
0.18%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 | |
| 0.0700 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold RVTY
| ETF | Share of the fund |
|---|---|
| TCAF T. Rowe Price Capital Appreciation Equ... | 1.29% |
| SPHB Invesco S&P 500 High Beta | 0.87% |
| DFSV DFA Investment Dimensions Group Inc. | 0.43% |
| TMSL T. Rowe Price Small-Mid Cap | 0.35% |
| DFAT DFA Investment Dimensions Group Inc. | 0.35% |
| ESML iShares ESG Aware MSCI USA Small-Cap | 0.28% |
| VBR Vanguard Small-Cap Value | 0.27% |
| SCHM Schwab U.S. Mid-Cap | 0.22% |
The eight funds with the largest weight in RVTY among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
RVTY stock splits
RVTY has split its stock 2 times since 1992. The latest was a 2-for-1 split on 4 Jun 2001.
Full RVTY stock split history →RVTY SEC filings
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations; Other events
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations; Other events
8-KSEC EDGAR
Shareholder vote results
DEF 14ASEC EDGAR
Proxy statement
10-KSEC EDGAR
Annual report
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.